Another recent trial of 69 patients with MET exon 14 skipping mutated-NSCLC treated with crizotinib demonstrated encouraging data with an ORR of 32%, a median PFS of 7.3 months, and a median OS of 20.5 months [95]. This evidence concerns the gene MET and non-small cell lung carcinoma.